CJC-1295 No DAC & Ipamorelin: Pre-Research Checklist

Before either compound enters your inventory, four things have to be settled: confirmed compound identity, a batch-specific certificate of analysis covering purity and contamination, documented storage and handling conditions, and a supplier whose test results you can verify yourself rather than take on faith. Everything downstream — tier pricing, minimum order quantities, reorder cadence, how fast you can restock — only matters after those four are locked. This is written for the business buyer stocking a catalog or a research inventory, not for anyone administering anything. Both compounds are research-use-only materials, not approved drugs, and nothing here is medical, veterinary, or legal guidance; those questions belong with your own licensed professionals and counsel.

Two compounds, two pathways, two different sourcing risks

CJC-1295 without DAC and ipamorelin get discussed together so often that buyers start treating them as one line item. They aren't, and the difference matters at the purchasing level.

CJC-1295 no DAC is a modified growth hormone-releasing hormone analog — a truncated GHRH fragment, sometimes referenced in the literature as Mod GRF 1-29. The "no DAC" designation means it lacks the Drug Affinity Complex moiety that extends circulating half-life in the DAC-modified version. That single structural difference is why mislabeling between the two variants is one of the more common identity problems in this category. A COA that says only "CJC-1295" without specifying the variant is not documentation; it's a guess.

Ipamorelin is a pentapeptide and a growth hormone secretagogue receptor ligand — a different receptor entirely. Research suggests its interest to investigators comes largely from selectivity relative to earlier secretagogues, and the published work on the two compound classes examines distinct signaling mechanisms. For your purposes as a buyer, the practical takeaway is narrower: these are different molecules with different molecular weights, different synthesis routes, and different impurity profiles. A supplier competent with one is not automatically competent with the other, and you should verify each independently, batch by batch.

That also means you cannot reason about quality by analogy. Strong HPLC results on an ipamorelin batch tell you nothing about the GHRH-analog batch shipping in the same box.

The documentation that has to arrive with the batch

The single most useful discipline in peptide procurement is refusing to accept generic paperwork. A product-level COA — one document that represents every batch of a compound a supplier has ever sold — is a marketing asset, not a quality record. What you want is batch-specific: the lot number on the vial matches the lot number on the analysis, and the analysis is dated.

Within that document, work through these questions in order.

Does the identity test confirm the exact variant? Mass spectrometry should return an observed mass consistent with the stated sequence. For CJC-1295 no DAC specifically, confirm the report reflects the non-DAC structure. If the sequence isn't printed anywhere in the documentation, ask for it in writing before you order.

What purity method was used, and is the chromatogram included? A stated purity figure with no attached HPLC trace is an assertion. The chromatogram lets a competent reviewer see peak shape, shoulder peaks, and whether the integration was done honestly. Suppliers who publish the trace are making a verifiable claim. Suppliers who publish only a percentage are asking for trust.

Is peptide content reported separately from gross weight? Lyophilized material includes counterions, residual water, and salts. Net peptide content and labeled vial weight are not the same number, and the gap is a legitimate cost variable across suppliers. Ask which figure the price is quoted against.

What contamination panels were run? Sterility, bacterial endotoxin, bioburden, residual solvents, and heavy metals are the categories that come up most often in serious research procurement. Which are appropriate depends on your application and your own quality system.

Who ran the tests? In-house testing is not disqualifying, but third-party analysis carries different weight. Either way, the report should name the lab and the method.

A verification table you can run against any quote

Use this as a pre-purchase pass. If a supplier can't clear the left column, the pricing conversation is premature.

The last two rows catch more bad suppliers than the technical ones. Charging for a COA, or releasing it only after the order clears, inverts the entire purpose of the document.

Storage, labeling and inventory control before the first order

Decide how you'll hold the material before it arrives, not after. Lyophilized peptides are generally shipped as a dry powder and are sensitive to temperature excursion, moisture, and light, and the specific conditions a supplier states for a given compound should govern — follow the batch documentation rather than a general rule you read somewhere.

Build the inventory controls first:

• Receiving log. Lot number, arrival date, condition on arrival, and the COA filed against that lot. If a question surfaces later, this log is the only thing that lets you answer it.
• Segregated storage by compound. The two compounds discussed here are visually indistinguishable as lyophilized powder. Physical separation and unambiguous labeling prevent the most avoidable error in the category.
• Research-use-only labeling maintained end to end. Whatever labeling obligations apply to your operation, they don't get satisfied by the supplier's label alone once material moves within your organization.
• A first-in, first-out rotation. Ordering to actual throughput rather than to a discount tier is usually the better economics, because material sitting past its documented handling window has no value at all.

Do not build a kit. Bundling compounds with reconstitution supplies changes what you are presenting, and it's a line worth keeping clean regardless of how customers ask for it.

Vetting the supplier behind the vial

Batch documentation tells you about one shipment. Supplier vetting tells you whether the next twelve will look the same. Consistency is the thing that actually determines whether you can build a catalog around a compound.

Ask how pricing is structured. Wholesale terms that are only revealed after a sales call are a structural choice, and it's a choice that usually means the number moves depending on who's asking. Published tier structures are easier to plan against. Margins, minimums, and landed cost vary widely by volume and category, so the useful question isn't "what's the rate" but "is the rate written down anywhere I can check before I commit."

Ask where fulfillment originates and what the realistic restock path looks like. Cross-border shipping introduces customs variability that can strand inventory. Domestic fulfillment shortens the loop between reorder and shelf.

Ask what happens when a batch changes. New synthesis lot, new COA — does the supplier proactively publish it, or do you have to request it every time? Ask whether historical COAs stay accessible after a lot sells through. A supplier who deletes old test records is telling you something.

Finally, ask about their own supply chain in general terms. You don't need proprietary detail, but a supplier who can't describe their testing workflow at all is one you're trusting rather than evaluating.

Compliance questions that belong with your counsel

This section deliberately answers nothing. The regulatory picture for research compounds is unsettled, varies by jurisdiction, and shifts — and any page that tells you flatly what is or isn't permitted in your state is selling confidence it doesn't have.

What this checklist can do is list the questions worth putting to your attorney and, where relevant, your state board before you buy:

• How should research-use-only material be classified, labeled, and recorded within our specific business structure?
• What does our professional licensing framework say about holding or transferring compounds of this category, and who at the state level interprets that?
• What recordkeeping obligations attach to inventory we hold, and for how long?
• If we resell, what disclosure and labeling requirements apply to us as distinct from those that applied to our supplier?
• What does our insurance carrier require or exclude?

Get answers in writing, from someone whose professional judgment covers your jurisdiction and your business model. This article is informational and is not legal advice.

What Real Peptides does differently

Real Peptides operates a Wholesale Partner Program built for businesses that run the verification process above rather than skipping it. Every compound in the catalog is tested to 99%+ HPLC purity, with a 7-panel testing regimen applied at the batch level. Certificates of analysis are publicly verifiable — a prospective buyer can read the lab results before applying, without a sales call, a deposit, or a fee for the document. That's the practical difference from a model where COAs are gated behind a purchase or sold separately.

Fulfillment runs from within the United States, with orders typically shipping in a 5–7 day window, which shortens the gap between a reorder decision and material on the shelf. The wholesale application itself is a 3-step process rather than an extended qualification cycle.

Both compounds covered here are catalog items: CJC-1295 No DAC 10mg and Ipamorelin 10mg are each available with their own batch documentation, and the related Tesamorelin 10mg sits in the same research category for buyers building out that section of a catalog.

Where a qualified buyer goes next

If you've worked the checklist and your remaining questions are about tier structure, minimums, and restock timing rather than whether the material is what the label says, you're at the point where the Wholesale Partner Program application is the right next step. Read the published COAs first — that's the part most buyers skip and the part that actually decides the question.

Buyers expanding beyond these two compounds can review the Growth Factor & Tissue Signaling Research collection, compare inventory staples in Popular Peptides, or look at adjacent categories such as Performance & Recovery Research and widely stocked items including BPC-157 10mg and TB-500 10mg.